Evaluation of the accelerate pheno system for identification of acinetobacter clinical isolates and minocycline susceptibility testing

Sarah L. Bowler, Justin W. Towne, Romney M. Humphries, Yohei Doi

研究成果: Article

抄録

The Accelerate Pheno system (AXDX) is a rapid phenotypic bacterial identification and susceptibility testing system which is approved for use with positive blood cultures. Acinetobacter baumannii is a nosocomial pathogen for which the limited treatment options include minocycline in the case of multidrug resistance. Here, we studied the performance of A. baumannii identification and minocycline susceptibility testing by AXDX using 101 contemporary Acinetobacter sp. clinical isolates. Overall, the sensitivity for A. baumannii and A. baumannii complex identification was 100% (73/73) and 97.6% (82/84), respectively. Specificity for A. baumannii complex identification was 86.6% (13/15). The essential agreement of minocycline susceptibility results (1 log 2 MIC agreement) of AXDX MICs with reference broth microdilution was 98.0% (96/98). There were no very major errors or major errors. Overall, 24.5% (24/98) of results yielded minor errors. AXDX reliably identified A. baumannii and predicted minocycline susceptibility results, which should help guide treatment choices in a timely manner for infections where options are limited.

元の言語English
記事番号e01711-18
ジャーナルJournal of clinical microbiology
57
発行部数3
DOI
出版物ステータスPublished - 03-2019

Fingerprint

Acinetobacter baumannii
Minocycline
Acinetobacter
Multiple Drug Resistance
Infection

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)

これを引用

@article{1b679e2fc24f4d56926771cccffa18f3,
title = "Evaluation of the accelerate pheno system for identification of acinetobacter clinical isolates and minocycline susceptibility testing",
abstract = "The Accelerate Pheno system (AXDX) is a rapid phenotypic bacterial identification and susceptibility testing system which is approved for use with positive blood cultures. Acinetobacter baumannii is a nosocomial pathogen for which the limited treatment options include minocycline in the case of multidrug resistance. Here, we studied the performance of A. baumannii identification and minocycline susceptibility testing by AXDX using 101 contemporary Acinetobacter sp. clinical isolates. Overall, the sensitivity for A. baumannii and A. baumannii complex identification was 100{\%} (73/73) and 97.6{\%} (82/84), respectively. Specificity for A. baumannii complex identification was 86.6{\%} (13/15). The essential agreement of minocycline susceptibility results (1 log 2 MIC agreement) of AXDX MICs with reference broth microdilution was 98.0{\%} (96/98). There were no very major errors or major errors. Overall, 24.5{\%} (24/98) of results yielded minor errors. AXDX reliably identified A. baumannii and predicted minocycline susceptibility results, which should help guide treatment choices in a timely manner for infections where options are limited.",
author = "Bowler, {Sarah L.} and Towne, {Justin W.} and Humphries, {Romney M.} and Yohei Doi",
year = "2019",
month = "3",
doi = "10.1128/JCM.01711-18",
language = "English",
volume = "57",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "3",

}

Evaluation of the accelerate pheno system for identification of acinetobacter clinical isolates and minocycline susceptibility testing. / Bowler, Sarah L.; Towne, Justin W.; Humphries, Romney M.; Doi, Yohei.

:: Journal of clinical microbiology, 巻 57, 番号 3, e01711-18, 03.2019.

研究成果: Article

TY - JOUR

T1 - Evaluation of the accelerate pheno system for identification of acinetobacter clinical isolates and minocycline susceptibility testing

AU - Bowler, Sarah L.

AU - Towne, Justin W.

AU - Humphries, Romney M.

AU - Doi, Yohei

PY - 2019/3

Y1 - 2019/3

N2 - The Accelerate Pheno system (AXDX) is a rapid phenotypic bacterial identification and susceptibility testing system which is approved for use with positive blood cultures. Acinetobacter baumannii is a nosocomial pathogen for which the limited treatment options include minocycline in the case of multidrug resistance. Here, we studied the performance of A. baumannii identification and minocycline susceptibility testing by AXDX using 101 contemporary Acinetobacter sp. clinical isolates. Overall, the sensitivity for A. baumannii and A. baumannii complex identification was 100% (73/73) and 97.6% (82/84), respectively. Specificity for A. baumannii complex identification was 86.6% (13/15). The essential agreement of minocycline susceptibility results (1 log 2 MIC agreement) of AXDX MICs with reference broth microdilution was 98.0% (96/98). There were no very major errors or major errors. Overall, 24.5% (24/98) of results yielded minor errors. AXDX reliably identified A. baumannii and predicted minocycline susceptibility results, which should help guide treatment choices in a timely manner for infections where options are limited.

AB - The Accelerate Pheno system (AXDX) is a rapid phenotypic bacterial identification and susceptibility testing system which is approved for use with positive blood cultures. Acinetobacter baumannii is a nosocomial pathogen for which the limited treatment options include minocycline in the case of multidrug resistance. Here, we studied the performance of A. baumannii identification and minocycline susceptibility testing by AXDX using 101 contemporary Acinetobacter sp. clinical isolates. Overall, the sensitivity for A. baumannii and A. baumannii complex identification was 100% (73/73) and 97.6% (82/84), respectively. Specificity for A. baumannii complex identification was 86.6% (13/15). The essential agreement of minocycline susceptibility results (1 log 2 MIC agreement) of AXDX MICs with reference broth microdilution was 98.0% (96/98). There were no very major errors or major errors. Overall, 24.5% (24/98) of results yielded minor errors. AXDX reliably identified A. baumannii and predicted minocycline susceptibility results, which should help guide treatment choices in a timely manner for infections where options are limited.

UR - http://www.scopus.com/inward/record.url?scp=85062263889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062263889&partnerID=8YFLogxK

U2 - 10.1128/JCM.01711-18

DO - 10.1128/JCM.01711-18

M3 - Article

C2 - 30651391

AN - SCOPUS:85062263889

VL - 57

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 3

M1 - e01711-18

ER -